Professor Jain is an internationally recognised expert in the management of prostate cancer. He treats patients with prostate cancer with advanced radiotherapy (stereotactic radiotherapy and brachytherapy) and drug therapy (chemotherapy, hormone therapy). He carried an international fellowship at University of Toronto in prostate cancer.
He is an innovator working to reduce side-effects and improve outcomes from prostate cancer treatment; he performed the first transperineal prostate biopsies, the first transperineal fiducial marker insertion and the first SpaceOAR insertion in Northern Ireland. He also introduced new services to NI, HDR brachytherapy for prostate cancer and stereotactic radiotherapy for prostate cancer and oligometastatic disease. He leads multiple drug and radiotherapy trials in Northern Ireland and is a member of trial management groups for national and international studies.
He is an invited member of the American Society of Clinical Oncology Genitourinary Guidelines Development Group, the UK National Cancer Research Institute’s prostate cancer clinical research group and the NI NICAN radiotherapy clinical reference group. He is past-Chair of the Irish Radiation Research Society. He is Co-Director of the FASTMAN UK Prostate Cancer of Excellence. He has published papers in the most important journals including New England Journal of Medicine, Lancet Oncology and Journal of Clinical Oncology. He strongly believes in educating the next generation of doctors towards a career in academic oncology.
Professor Suneil Jain recently joined us to discuss Prostate Health in our HealthStyle Podcast. Check it out below:
Professor of Clinical Oncology, Queen’s University Belfast
Consultant in Clinical Oncology, NI Cancer Centre, Belfast Health and Social Care Trust
Prof Jain has 3 young kids, he enjoys many sports including running, golf and football, travel and playing guitar.
Sunnybrook Health Sciences Centre, Toronto – 2011 - 2012
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology. 2020
A phase II randomized trial of the poly (ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. Lancet Oncology 2019
Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study. International Journal of Radiation Oncology Biology and Physics. 104, 1066-1073.
Observed high incidence of prostatic calculi with the potential to act as natural fiducials for prostate image guided radiotherapy. Technical Innovations & Patient Support in Radiation Oncology 9, 35-40.
A pilot study of patient reported outcomes evaluating treatment related symptoms and quality of life for men receiving high dose rate brachytherapy combined with hypo-fractionated radiotherapy or hypo-fractionated radiotherapy alone for the treatment of localised prostate
Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine 31, 182-189
UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016. Journal of Contemporary Brachytherapy 10, 238-245
Efficacy of a rectal spacer with prostate SABR—first UK experience. British Journal of Radiology 91
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clinical Oncology 30, 5-14
Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Annals of Oncology 29, 215-222
An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology. Cancer Nanotechnology 8
A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy. Radiation Oncology 12
Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter. International Journal of Radiation Oncology Biology Physics 98, 419-427
Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics 97, 822-829
Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. Radiation Oncology
Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. Journal of Urology 196, 1651-1658
Class solutions for SABR-VMAT for high-risk prostate cancer with and without elective nodal irradiation. Radiation Oncology
Active surveillance for the management of localized prostate cancer (Cancer Care Ont. guideline): American society of clinical oncology clinical practice guideline endorsement. Journal of Clinical Oncology 34, 2182-96
Fiducial marker guided prostate radiotherapy: A review. British Journal of Radiology 89
Sector analysis provides additional spatial information on the permanent prostate brachytherapy learning curve. Brachytherapy 14, 703-710
Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. Journal of Clinical Oncology 33, 272-277
Gleason upgrading with time in a large prostate cancer active surveillance cohort. Journal of Urology 194, 79-84
DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine 373, 1697-1708
Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiotherapy and Oncology 110, 342-347
Help & Support